Sandoz Group AG (SDZNY)
OTCMKTS
· Delayed Price · Currency is USD
54.10
+0.42 (0.77%)
Jun 27, 2025, 3:45 PM EDT
Sandoz Group AG Revenue
In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth. Sandoz Group AG had revenue of $5.32B in the half year ending December 31, 2024, with 14.92% growth.
Revenue
10.38B
Revenue Growth
+4.06%
P/S Ratio
2.20
Revenue / Employee
470.95K
Employees
22,049
Market Cap
22.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
| Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
| Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
| Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
| Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Sandoz Group AG News
- 11 days ago - Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee - Fortune
- 12 days ago - Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor - Benzinga
- 26 days ago - Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] - GlobeNewsWire
- 5 weeks ago - Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars - GlobeNewsWire
- 2 months ago - Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed - GlobeNewsWire
- 2 months ago - Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar - Seeking Alpha
- 2 months ago - Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications - GlobeNewsWire